Vivos Inc. Provides Intellectual Property Protection Update
May 12, 2022 09:30 ET
|
Vivos Inc.
Richland WA, May 12, 2022 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to report that it expanded its intellectual property protection on several fronts. Our patent team filed...
Vivos Inc Implements Multiple Patient IsoPet® Therapy Day
April 21, 2022 09:30 ET
|
Vivos Inc.
Richland WA, April 21, 2022 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce a combined IsoPet® therapy schedule into one treatment day, allowing for one production run...
Vivos Inc. Enhances its Intellectual Property Protection
February 24, 2022 09:30 ET
|
Vivos Inc.
Richland WA, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to report that it filed its particle patent in several countries. Our new patent team filed the...
Vivos Inc. Provides 2021 Recap and Outlines 2022 Objectives
January 24, 2022 09:30 ET
|
Vivos Inc.
Richland WA, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), provides 2021 recap and outlines future objectives. Vivos’ CEO, Dr. Mike Korenko stated, “as we begin 2022, we wanted to...
Vivos Inc Completes Certification Training Modules for Future IsoPet® Therapy Regional Clinics
September 22, 2021 09:30 ET
|
Vivos Inc.
Richland WA, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc working with FX Masse completed nine certification training modules that are part of the certification training...
Global Radiotherapy Market (2021 to 2026) - Rising Healthcare Expenditure Across Developing Countries Presents Opportunities
July 01, 2021 05:09 ET
|
Research and Markets
Dublin, July 01, 2021 (GLOBE NEWSWIRE) -- The "Global Radiotherapy Market by Product (LINAC, CyberKnife, Gamma Knife, Tomotherapy, Particle Therapy, Cyclotron), Procedure (External (IMRT, IGRT,...
Vivos Inc Initiates Isopet® Therapy in Horses
June 24, 2021 09:30 ET
|
Vivos Inc.
Richland WA, June 24, 2021 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) Vivos Inc announced that it has completed the first IsoPet® therapy on an equoid tumor. It was administered at the University...
Global Radiopharmaceutical Market (2020 to 2025) - by Type, Application, Procedure, End-user and Geography
March 15, 2021 06:28 ET
|
Research and Markets
Dublin, March 15, 2021 (GLOBE NEWSWIRE) -- The "Global Radiopharmaceutical Market (2020-2025) by Type, Application, Procedure, End-User, Geography, Competitive Analysis and the Impact of Covid-19...
Vivos Inc Receives Feedback from FDA on Breakthrough Designation Request
January 19, 2021 09:30 ET
|
Vivos Inc.
Richland WA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Although we were unable to secure a Breakthrough Device Designation from the FDA, this was a well-designed process that...
Rafarma Merger Company Bebig Approved For Production And Sale Of Yttrium-90 For Treatment Of Inoperable Liver Cancer
December 09, 2020 09:15 ET
|
RAFARMA PHARMACEUTICALS INC
Nicosia, Cyprus, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) is pleased to announce that one of the acquisition companies of the previously-announced Biocogency...